GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anixa Biosciences Inc (NAS:ANIX) » Definitions » Shiller PE Ratio

Anixa Biosciences (Anixa Biosciences) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 1989. Start your Free Trial

What is Anixa Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences Shiller PE Ratio Historical Data

The historical data trend for Anixa Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anixa Biosciences Shiller PE Ratio Chart

Anixa Biosciences Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anixa Biosciences Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anixa Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Anixa Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Shiller PE Ratio falls into.



Anixa Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anixa Biosciences's E10 for the quarter that ended in Apr. 2024 is calculated as:

For example, Anixa Biosciences's adjusted earnings per share data for the three months ended in Apr. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Apr. 2024 (Change)*Current CPI (Apr. 2024)
=-0.1/131.7762*131.7762
=-0.100

Current CPI (Apr. 2024) = 131.7762.

Anixa Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201407 0.036 100.520 0.047
201410 -0.319 100.176 -0.420
201501 0.373 98.604 0.498
201504 -0.237 99.824 -0.313
201507 -0.164 100.691 -0.215
201510 -0.137 100.346 -0.180
201601 -0.164 99.957 -0.216
201604 -0.150 100.947 -0.196
201607 -0.130 101.524 -0.169
201610 -0.120 101.988 -0.155
201701 -0.410 102.456 -0.527
201704 0.020 103.167 0.026
201707 -0.120 103.278 -0.153
201710 -0.110 104.070 -0.139
201801 -0.110 104.578 -0.139
201804 -0.080 105.708 -0.100
201807 -0.300 106.324 -0.372
201810 -0.290 106.695 -0.358
201901 -0.250 106.200 -0.310
201904 -0.130 107.818 -0.159
201907 -0.110 108.250 -0.134
201910 -0.100 108.577 -0.121
202001 -0.130 108.841 -0.157
202004 -0.120 108.173 -0.146
202007 -0.110 109.318 -0.133
202010 -0.090 109.861 -0.108
202101 -0.090 110.364 -0.107
202104 -0.080 112.673 -0.094
202107 -0.140 115.183 -0.160
202110 -0.130 116.696 -0.147
202201 -0.130 118.619 -0.144
202204 -0.120 121.978 -0.130
202207 -0.090 125.002 -0.095
202210 -0.120 125.734 -0.126
202301 -0.080 126.223 -0.084
202304 -0.070 127.992 -0.072
202307 -0.080 128.974 -0.082
202310 -0.090 129.810 -0.091
202401 -0.100 130.124 -0.101
202404 -0.100 131.776 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences  (NAS:ANIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anixa Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Anixa Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anixa Biosciences (Anixa Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Executives
Amit Kumar director, officer: Chief Executive Officer C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Michael Catelani officer: COO & CFO 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Titterton Lewis H Jr director 6 AUTUMN LANE, SARATOGA SPRINGS NY 12866
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Emily Gottschalk director 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE CA 95118
John J Monahan director
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Richard H Williams director C/O QUOKKA SPORTS INC, 525 BRANNAN ST GROUND FL, SAN FRANCISCO CA 94108
Dale Fox director 929 NOWITA PLACE, VENICE CA 90291
Andrea Belz director 1011 ALTA VISTA DRIVE, ALTADENA CA 91001
Tisha Stender officer: Chief Operating Officer 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Robert Andrew Berman officer: President and CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
John H. Roop officer: Sr. Vice President-Engineering C/O COPYTELE, INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747
Bruce F Johnson director 20 S. WACKER DR, CHICAGO IL 60606
Kent B. Williams director C/O COPYTELE INC., 900 WALT WHITMAN ROAD, MELVILLE NY 11747